US Doctor Requests Temporary FDA Approval of Psychedelics to Fight Covid-19 Related Trauma

July 9, 2020 09:05:48

As COVID-19 continues to wreak havoc globally, it seems medics may have to turn to psychedelics to help deal with the anxiety and depression triggered by the pandemic. Psychedelic-based medications currently feature three major substances; MDMA, LSD, and Psilocybin, commonly referred to as Magic Mushrooms.

Psychedelics are yet to be legalized worldwide because of the stigma attached to the ‘drug.’ The good news is that clinical studies are providing accurate data about these substances, and are revealing how effective they are when administered under medical supervision.

U.S. psychiatrist Dr. Morgan Campbell recently brought the matter to light while addressing the U.S. Food and Drug Administration (“FDA”). He asked the agency to approve the therapeutic use of psychedelic medicines, at least temporarily. He said this was the best solution to help deal with the mental suffering caused by the COVID-19 pandemic.

Usually, the approval protocols take years, sometimes even decades before a drug is readily available to be prescribed by physicians. Due to the rise of trauma COVID-19 is causing, the doctor wants the FDA to approve the therapies temporarily. Psychedelics are associated with the treatment of mental disorders, such as PTSD.

He wrote his plea earlier this week in a publication of The Sacramento Bee. Dr. Campbell projects that cases of mental illnesses will multiply in the post-COVID new normal as people come to terms with the reality of what has happened to their families, their businesses, their jobs and to social interactions in general.

Studies show that psychedelics may be the better choice compared to current drugs. It seems the FDA is leaning towards approving the medicine after it recently sped up Psilocybin and MDMA’s breakthrough status.

Dr. Campbell believes that the drug’s approval can help flatten the curve and reduce the number of patients visiting hospitals. His statement reads, “Speedily addressing psychiatric issues with the best therapies available can similarly protect our healthcare system.”

Psilocybin and MDMA are proving to be safe drugs, and there’s a lot of quality evidence to support these claims by clinicians and researchers. The only challenge it may face is the stigma that some may have towards psychedelics.

Previously, it was assumed that it was harmful, and the federal government criminalized it. However, recent developments seem to favor the medicine as the best option for therapies to treat addiction and other mental illnesses.

It would be interesting to hear what well-established psychedelics companies like Pure Extracts Corp. have to say about this request for temporal permission for the use of psychedelics in the fight against COVID-19 related trauma.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.